Edwards Lifesciences Earnings: Strong Performance Puts Firm on Track to Meet Our 2026 Expectations
Edwards delivered second-quarter performance that included $1.74 billion in revenue, up 13% in constant currency, fueled by transcatheter aortic valve replacement growth of 11% and strong double-digit growth in transcatheter mitral and tricuspid.